Abstract | BACKGROUND: METHODS AND RESULTS: Single nucleotide polymorphisms of CYP2C19*2, *3, CYP3A4 (IVS10 +12G>A) and P2Y(12) (T744C) were determined in 25 PCI-scheduled patients who had been systematically analyzed for the antiplatelet effect of clopidogrel in a previous study. On the basis of CYP2C19 genotype, 11 patients (44%) were classified as extensive metabolizers (EMs), 8 (32%) as intermediate metabolizers (IMs) and 6 (24%) as poor metabolizers (PMs). The rates of inhibition of 5 micromol/L ADP-induced platelet aggregation by clopidogrel intake at 48 h were 31.6 +/-14.3% in EMs, 18.4 +/-10.0% in IMs (P=0.04 vs EMs) and 16.0 +/-13.0% in PMs (P=0.02 vs EMs). CONCLUSIONS:
CYP2C19 polymorphisms are frequent in Japanese, and the antiplatelet effect of clopidogrel is strongly affected by them in the real-world clinical setting.
|
Authors | Toshikazu Jinnai, Hisanori Horiuchi, Takeru Makiyama, Junichi Tazaki, Tomohisa Tada, Masaharu Akao, Koh Ono, Kozo Hoshino, Yumiko Naruse, Kanako Takahashi, Haruyo Watanabe, Toru Kita, Takeshi Kimura |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 73
Issue 8
Pg. 1498-503
(Aug 2009)
ISSN: 1347-4820 [Electronic] Japan |
PMID | 19531897
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Receptors, Purinergic P2
- Adenosine Diphosphate
- Clopidogrel
- Aryl Hydrocarbon Hydroxylases
- CYP2C19 protein, human
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 CYP3A
- CYP3A4 protein, human
- Ticlopidine
|
Topics |
- Adenosine Diphosphate
(pharmacology)
- Aged
- Aryl Hydrocarbon Hydroxylases
(genetics)
- Clopidogrel
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 CYP3A
(genetics)
- Female
- Humans
- Japan
(epidemiology)
- Male
- Middle Aged
- Pharmacogenetics
- Platelet Aggregation
(drug effects)
- Platelet Aggregation Inhibitors
(pharmacology)
- Polymorphism, Single Nucleotide
(physiology)
- Receptors, Purinergic P2
(genetics)
- Ticlopidine
(analogs & derivatives, pharmacology)
|